Retail Price: $918+You Save: About $589+ Product Review SHIPPING INFO This is a refrigerated product
reliable contraception should be in place, and any plans to conceive should be discussed with a clinician before starting or stopping treatment If you experience any of the following whilst using retatrutide or any weight-loss agent, seek prompt medical attention: Severe or persistent nausea, vomiting, or abdominal pain particularly pain radiating to the back, which may indicate pancreatitis Right upper quadrant pain, jaundice, or fever, which may suggest gallbladder disease Persistent vomiting with reduced urine output or signs of dehydration Signs of low blood sugar (shakiness, sweating, confusion, dizziness) Rapid or irregular heartbeat Unexplained muscle weakness or pain Rash, swelling of the face or throat, or difficulty breathing, which may indicate a serious allergic reaction Retatrutide has no UK marketing authorisation
Medical approval: In 2019, the FDA approved PT-141 under the trade name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women
Some states have explicitly banned compounding of non-approved drugs
